Prenatal and Childhood Growth, Chemerin Concentrations, and Metabolic Health in Adult Life

Autor: Mika Venojärvi, Clive Osmond, Johan G. Eriksson
Přispěvatelé: School of Medicine / Biomedicine, Clinicum, Johan Eriksson / Principal Investigator, Department of General Practice and Primary Health Care
Rok vydání: 2016
Předmět:
medicine.medical_specialty
Waist
Article Subject
Endocrinology
Diabetes and Metabolism
medicine.medical_treatment
NONDIABETIC OBESE
030209 endocrinology & metabolism
Type 2 diabetes
030204 cardiovascular system & hematology
lcsh:Diseases of the endocrine glands. Clinical endocrinology
Body fat percentage
Preeclampsia
03 medical and health sciences
0302 clinical medicine
Endocrinology
INFLAMMATION
Internal medicine
Diabetes mellitus
medicine
Chemerin
lcsh:RC648-665
BIRTH COHORT
PLASMA
biology
Endocrine and Autonomic Systems
business.industry
Insulin
DIABETES-MELLITUS
SERUM-LEVELS
medicine.disease
INSULIN
3. Good health
PREECLAMPSIA
ADIPOSE-TISSUE
ADIPOKINE CHEMERIN
3121 General medicine
internal medicine and other clinical medicine
biology.protein
Metabolic syndrome
business
Research Article
Zdroj: International Journal of Endocrinology
International Journal of Endocrinology, Vol 2016 (2016)
ISSN: 1687-8345
1687-8337
DOI: 10.1155/2016/3838646
Popis: Article
Several noncommunicable diseases have their origins in early developmental phases. One factor possibly explaining the association between early growth and later health could be adipocyte function. The objective of this study was to assess the association between the adipocytokine chemerin and early growth and later health. 1074 participants from Helsinki Birth Cohort Study born 1934–1944 with information on prenatal and childhood growth participated. Metabolic outcomes include glucose tolerance, adiposity, and chemerin concentration. Mean chemerin concentrations were 5.0 ng/mL higher in women than in men (95% CI 2.7 to 7.2, ). The strongest correlate of chemerin concentration was adult waist circumference and body fat percentage (, and , , resp.). After adjustment for body fat percentage, chemerin concentration was 5.4 ng/mL lower in subjects with type 2 diabetes than in those with normal glucose tolerance (−0.2 to 10.9, ). It was 3.0 ng/mL higher in those with metabolic syndrome than in those without (0.6 to 5.3, ). No measure of early growth was associated with chemerin concentration. Our findings do not support a role for chemerin in linking early growth with later metabolic health.
published version
peerReviewed
Databáze: OpenAIRE
Externí odkaz: